-
4-aminopyridine Treatment for Nerve Injury
NCT03701581 ·
Phase: Phase 2, Phase 3 ·
Ages: 45 Years to 75 Years ·
Sex: Male
· New York: Rochester
-
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
NCT04868604 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York, Williamsville
-
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
NCT07103018 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New Hyde Park, New York
-
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
NCT07488923 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
NCT05932862 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
NCT06785636 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: White Plains
-
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
NCT05593497 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: The Bronx
-
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
NCT06906471 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: Male
· New York: New York
-
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
NCT06347705 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
NCT07730021 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer
NCT07335796 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Changes to Prostate Procedures
NCT06986083 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Commack, Harrison, New York, Uniondale
-
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
NCT07189403 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
NCT07277270 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo, New York
-
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
NCT07082920 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Lower Dose Radiation Therapy for People With Prostate Cancer
NCT07635238 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Commack, Harrison, New York, Uniondale
-
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Lake Success
-
A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer
NCT07225309 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Mental Health Care in People With Cancer
NCT06037954 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 65 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Albany, New York, Syracuse
-
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Syracuse
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
NCT07319871 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Brooklyn, Mineola, New York
-
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Mineola, New York, The Bronx
-
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Brooklyn, Mineola, New York
-
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT06533644 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Lake Success, New York
-
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
NCT06844383 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
A Study of Tarlatamab for People With Prostate Cancer
NCT07111507 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Commack, Harrison, New York, Uniondale
-
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
NCT06457919 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Commack, Harrison, New York, Uniondale
-
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Buffalo, New York, Rochester, The Bronx
-
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07244341 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Lake Success
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
NCT07213674 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: East Syracuse, New York
-
A Study of a New PET Scanner in People With Cancer
NCT07690917 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
NCT05751434 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Commack, Harrison, New York, Rockville Centre
-
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Buffalo, Mineola, New York, Syracuse
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
NCT05530655 ·
Phase: Early Phase 1 ·
Ages: 18 Years to 70 Years ·
Sex: Male
· New York: Rochester
-
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
NCT07540572 ·
Phase: Phase 1 ·
Ages: 18 Years to 99 Years ·
Sex: All (male and female)
· New York: Lake Success
-
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: The Bronx
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Commack
-
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07287150 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: The Bronx
-
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
NCT05125016 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Buffalo
-
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
NCT03972657 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York, Rochester
-
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
NCT07285694 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
NCT06397703 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
NCT06141993 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer
NCT06579417 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT05351424 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New Hyde Park, New York
-
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
NCT05422911 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York, The Bronx, Wappingers Falls
-
Ablative Therapy in the Management of Prostate Cancer
NCT03492424 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
Access to Genetic Testing in Underserved Patients With Cancer
NCT06422455 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Rochester
-
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
NCT05915442 ·
Phase: Phase 2 ·
Ages: 18 Years to 99 Years ·
Sex: Male
· New York: New York
-
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414 ·
Phase: Phase 3 ·
Ages: 18 Years to 100 Years ·
Sex: Male
· New York: New York, Syracuse, The Bronx
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
NCT06235697 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Lake Success, New York
-
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
NCT05629494 ·
Phase: Phase 4 ·
Ages: 18 Years to 80 Years ·
Sex: Male
· New York: Albany
-
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
Brodalumab in the Treatment of Immune-Related Adverse Events
NCT06673329 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
CUIMC Focal Therapy Registry
NCT07623941 ·
Phase: Not specified ·
Ages: 40 Years to 85 Years ·
Sex: Male
· New York: New York
-
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: Middletown
-
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York, The Bronx
-
Clinical Outcomes in Prostate Cancer Patients Undergoing HIFU Ablation
NCT07203482 ·
Phase: Not specified ·
Ages: 40 Years to 95 Years ·
Sex: Male
· New York: Brooklyn, New York
-
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
NCT03067051 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
Clinical Trial of Approaches to Prostate Cancer Surgery
NCT05155501 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years to 80 Years ·
Sex: Male
· New York: Flushing, New York
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· New York: Elmhurst, Elmira, Glens Falls, Jamaica
-
Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis
NCT06830265 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer
NCT07548164 ·
Phase: Phase 3 ·
Ages: No age limits stated ·
Sex: Male
· New York: Commack, Harrison, New York, Uniondale
-
Comprehensive Assessment of Cancer Theranostic Response
NCT06815354 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
Comprehensive Outcomes for After Cancer Health
NCT05349227 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
NCT04751435 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn, Jamaica, New York, Richmond Hill
-
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
NCT07285057 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: Male
· New York: The Bronx
-
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Effect of Text Message Reminders on M-ISI Score After Prostate Surgery
NCT07071207 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· New York: Rochester
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
NCT06559059 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: Brooklyn, Jamaica, New York, Staten Island
-
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
NCT05948657 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy
NCT06542757 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· New York: New York
-
Feasibility of Timesaving When Using Histolog Confocal Laser Endomicroscopy for Margin Assessment in Prostatectomy Specimen
NCT07141121 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York
-
Fusion or Cognitive Ultrasound-guided Biopsy to Detect Prostate Cancer
NCT06517901 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· New York: Albany
-
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
NCT02706561 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 21 Years and older ·
Sex: Male
· New York: New York
-
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)
NCT07567027 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 40 Years to 95 Years ·
Sex: Male
· New York: New York
-
Integrated Cancer Repository for Cancer Research
NCT02012699 ·
Phase: Not specified ·
Ages: 19 Years to 110 Years ·
Sex: All (male and female)
· New York: Glens Falls, Utica
-
Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy
NCT06172283 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: Male
· New York: Buffalo
-
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT03151629 ·
Phase: Not specified ·
Ages: 21 Years and older ·
Sex: Male
· New York: Brooklyn, Buffalo, New York
-
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
NCT06343077 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Male
· New York: New York